Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
C$2.50
+8.7%
C$2.05
C$1.02
C$30.90
C$107.65M1.365,506 shs11,969 shs
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$3.14
+16.7%
C$2.61
C$1.50
C$5.00
C$767.75M2.99,083 shs22,775 shs
Decibel Therapeutics, Inc. stock logo
DBTX
Decibel Therapeutics
$4.91
-0.8%
$5.00
$1.61
$5.40
$123.39M-0.43122,002 shs1.26 million shs
NexImmune, Inc. stock logo
NEXI
NexImmune
$0.02
$0.00
$7.05
N/A1.946,478 shs4 shs
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
$8.39
-7.8%
$7.40
$5.00
$17.40
$11.48M0.2745,552 shs3,030 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
+8.70%+106.61%+5.04%-14.09%-91.75%
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
+16.73%-5.14%+32.49%+84.71%-30.22%
Decibel Therapeutics, Inc. stock logo
DBTX
Decibel Therapeutics
0.00%0.00%0.00%0.00%0.00%
NexImmune, Inc. stock logo
NEXI
NexImmune
0.00%0.00%0.00%0.00%-100.00%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-7.85%-7.59%+28.27%+13.42%-34.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/AN/AN/AN/AN/AN/AN/AN/A
Decibel Therapeutics, Inc. stock logo
DBTX
Decibel Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
N/AN/AN/AN/AN/AN/AN/AN/A
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
4.6666 of 5 stars
3.73.00.04.83.31.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
4.00
Strong BuyN/AN/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
0.00
N/AN/AN/A
Decibel Therapeutics, Inc. stock logo
DBTX
Decibel Therapeutics
0.00
N/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
0.00
N/AN/AN/A
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
3.33
Buy$90.00973.22% Upside

Current Analyst Ratings Breakdown

Latest BU, APS, SNSE, DBTX, and NEXI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$100.00
5/1/2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/AN/AC$1.56 per share1.60C($0.92) per shareN/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$724.40K1,059.84C$0.08 per share39.00C$0.02 per share127.89
Decibel Therapeutics, Inc. stock logo
DBTX
Decibel Therapeutics
N/AN/AN/AN/A$3.28 per shareN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
N/AN/AN/AN/A$3.32 per shareN/A
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/AN/AN/AN/A$30.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
-C$154.69M-C$5.02N/AN/AN/A1,017.48%-136.29%N/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
-C$12.74M-C$0.06N/AN/A-1,758.62%-185.21%-39.22%N/A
Decibel Therapeutics, Inc. stock logo
DBTX
Decibel Therapeutics
-$63.01M-$2.53N/AN/AN/AN/A-84.03%-53.90%N/A
NexImmune, Inc. stock logo
NEXI
NexImmune
-$32.34M-$18.54N/AN/AN/AN/A-534.32%-213.72%8/5/2025 (Estimated)
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$30.16M-$23.00N/AN/AN/AN/A-66.72%-57.10%8/5/2025 (Estimated)

Latest BU, APS, SNSE, DBTX, and NEXI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$6.20N/AN/AN/AN/AN/A
5/6/2025Q1 2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$4.20-$5.40-$1.20-$0.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/A0.39%N/AN/AN/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/A4.45%N/AN/AN/A
Decibel Therapeutics, Inc. stock logo
DBTX
Decibel Therapeutics
N/AN/AN/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
N/AN/AN/AN/AN/A
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
-117.37
1.05
5.41
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
187.90
5.63
1.71
Decibel Therapeutics, Inc. stock logo
DBTX
Decibel Therapeutics
N/A
3.03
3.03
NexImmune, Inc. stock logo
NEXI
NexImmune
N/A
0.66
0.66
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/A
6.82
6.82

Institutional Ownership

CompanyInstitutional Ownership
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
15.10%
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
0.21%
Decibel Therapeutics, Inc. stock logo
DBTX
Decibel Therapeutics
69.59%
NexImmune, Inc. stock logo
NEXI
NexImmune
9.85%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
10.50%

Insider Ownership

CompanyInsider Ownership
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
17.11%
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
28.06%
Decibel Therapeutics, Inc. stock logo
DBTX
Decibel Therapeutics
35.60%
NexImmune, Inc. stock logo
NEXI
NexImmune
14.90%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
23.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
3143.06 millionN/ANot Optionable
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
20244.51 millionN/ANot Optionable
Decibel Therapeutics, Inc. stock logo
DBTX
Decibel Therapeutics
6825.13 million16.18 millionNot Optionable
NexImmune, Inc. stock logo
NEXI
NexImmune
61.40 million1.19 millionNot Optionable
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
401.26 million968,000Not Optionable

Recent News About These Companies

Sensei Rockets on FY ’24 Results
Sensei Rockets on FY ’24 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aptose Biosciences stock logo

Aptose Biosciences TSE:APS

C$2.50 +0.20 (+8.70%)
As of 07/11/2025 03:55 PM Eastern

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Burcon NutraScience stock logo

Burcon NutraScience TSE:BU

C$3.14 +0.45 (+16.73%)
As of 07/11/2025 03:59 PM Eastern

Burcon NutraScience Corporation, together with its subsidiaries, develops plant proteins and ingredients for use in the food and beverage industries in Canada. The company offers Peazazz and Peazac, a pea protein for use in dairy alternatives, ready-to-drink beverages, dry blended beverages, bars, baked goods, and meat substitute products. It provides Puratein, a canola protein isolate for use in meat alternatives, such as burgers, sausages, and nutrition bars; Supertein, a canola protein that is a light-colored powder for use in non-dairy frozen desserts, egg alternative, plant-based marshmallows and ready-to-mix beverages, whipped toppings, and plant-based bars; and Nutratein, a canola protein comprising a mixture of globulin and albumin proteins for use in meat and egg alternatives, and other plant-based functional foods. In addition, the company offers Nutratein-PS, a blend of Peazazz pea protein and Supertein canola protein; Nutratein-TZ, a blend of Peazac pea protein and Puratein canola protein; and CLARISOY, a soy protein for use in sports nutrition beverages, citrus-based drinks, fruit-flavored beverages, lemonades, powdered beverage mixes, and non-beverage plant-based products. The company was formerly known as Burcon Capital Corp. and changed its name to Burcon NutraScience Corporation in October 1999. The company was incorporated in 1998 and is headquartered in Vancouver, Canada.

Decibel Therapeutics stock logo

Decibel Therapeutics NASDAQ:DBTX

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. As of September 25, 2023, Decibel Therapeutics, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.

NexImmune stock logo

NexImmune NASDAQ:NEXI

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Sensei Biotherapeutics stock logo

Sensei Biotherapeutics NASDAQ:SNSE

$8.39 -0.71 (-7.85%)
Closing price 07/11/2025 03:56 PM Eastern
Extended Trading
$8.45 +0.06 (+0.76%)
As of 07/11/2025 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.